Physician profile
Esther E Knapp
NPI 1275785479
$1,222.68
in general payments reported to CMS, 2019-2025
14 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $167 · 2021: $109 · 2022: $166 · 2023: $23.87 · 2024: $24.03 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genetix Biotherapeutics INC | $209.99 | 2025 | Lyfgenia |
| Alexion Pharmaceuticals, INC. | $166.78 | 2020 | |
| Adaptive Biotechnologies Corporation | $146.00 | 2022 | |
| Sobi, INC | $124.97 | 2025 | |
| Jazz Pharmaceuticals INC. | $120.66 | 2025 | |
| Amgen INC. | $109.20 | 2021 | |
| Glaxosmithkline, LLC. | $94.30 | 2025 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $66.38 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $42.00 | 2025 | |
| Novo Nordisk INC | $38.25 | 2025 | |
| Rare Disease Therapeutics, INC. | $36.55 | 2025 | Purixan, Xromi |
| Pfizer INC. | $24.03 | 2024 | |
| Servier Pharmaceuticals LLC | $23.87 | 2023 | |
| Mallinckrodt Hospital Products INC. | $19.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.